What is Biolife?
Biolife Delaware, LLC operates as a specialized developer of advanced medical device products, most notably recognized for its proprietary StatSeal and WoundSeal technologies. These solutions are engineered to address critical clinical requirements in hemostasis and wound management, providing healthcare providers with essential tools to improve patient outcomes. Following its acquisition by Merit Medical Systems, Biolife has been integrated into a broader portfolio, enhancing the parent company's ability to deliver comprehensive, high-efficacy medical solutions. The company's focus remains on the intersection of innovation and clinical reliability, positioning it as a key asset in the medical technology sector.
How much funding has Biolife raised?
Biolife has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Biolife
PPP
Public-Private Partnership
What's next for Biolife?
With the backing of Merit Medical Systems, Biolife is poised to scale its operational footprint and accelerate the distribution of its core product lines. The strategic integration suggests a focus on expanding market penetration for StatSeal and WoundSeal, leveraging Merit's established global infrastructure. Future developments will likely center on optimizing manufacturing efficiencies and exploring new clinical applications for their existing hemostasis portfolio. As the company transitions into this new phase of growth, the emphasis will remain on maintaining high standards of clinical efficacy while capitalizing on the synergies created by the acquisition to drive long-term value for stakeholders and healthcare providers alike.
See full Biolife company page
